As the antibacterial drug market continues to expand, pharmaceutical companies are accelerating the deployment of innovative drugs

Antibacterial drugs refer to drugs that can inhibit or kill bacteria and are used to prevent and treat bacterial infections
.
There are many kinds of antibacterial drugs
.
Among them, systemic anti-infective drugs are one of the main types of drugs on the market
.
According to statistics, in 2019, China's public medical institutions accounted for 18.
87% of the market share of the terminal chemical drugs sales of 1,094.
6 billion yuan in 2019
.
China is a big country in the use of antibiotics, and the market has been expanding year by year
.
It is worth noting that at the same time, more systemic anti-infective drugs are also emerging in China
.
For example, Zai Lab's two new class 1 drugs, omacycline tosylate tablets and omacycline tosylate for injection, were approved for marketing, becoming the fourth and fifth systemic antibacterial innovative drugs approved this year
.
According to data, omacycline tosylate is a product introduced by Zai Lab from Paratek in 2017
.
In March 2020, Zai Lab signed an exclusive promotion agreement with Huizheng (Shanghai) Pharmaceutical Technology, the Sun company of Hisun Pharmaceuticals
.
Specifically, omacycline tosylate is a new type of tetracycline, specifically designed to overcome the resistance of tetracycline and improve the activity against a broad spectrum of bacterial infections
.
Omacycline tosylate is a new type of tetracycline, specifically designed to overcome the resistance of tetracycline and improve the activity against a broad spectrum of bacterial infections
.
The new drug is available in both an intravenous injection form and a once-a-day oral dosage form
.
In addition to the above two drugs, there are still 3 systemic antibacterial class 1 new drugs that have been clinically declared and approved since 2021, two of which are biological drugs class 1 new drugs: Xingmeng Biomedicine's recombinant anti-staphylococcus aureus toxin human The approved indication for the sourced monoclonal antibody injection is for the treatment of severe pneumonia caused by Staphylococcus aureus toxin infection, and the approved indication for TNM002 injection of Zhuhai Technomicrobiology is the prevention of tetanus
.
In the future, with the continuous improvement of domestic R&D technology, the industry expects that the field of antibacterial drugs in my country will usher in a wave of innovation
.
In fact, from the number of systemic antibacterial Class 1 new drugs approved this year, it only took less than half a year from the listing to the successful entry into the medical insurance catalog.
It can be seen that the priority review system has continuously accelerated the process of launching innovative drugs.
The dynamic adjustment of the medical insurance catalog has greatly accelerated the time for new drugs to enter medical insurance after approval.
The national level of support for innovative drugs has begun to show results.
Not only are companies being encouraged to accelerate innovation, more and more patients will also benefit
.
However, it should be noted that although China is a country that uses antibiotics and has a large clinical demand for the drug, from the current market situation, it has become a trend that the systemic antibacterial drugs included in the country have experienced "price reduction pain".

.
It is reported that in the previous five rounds of six batches of national mining, systemic antibacterial drugs were included in each batch, and the numbers were 1, 7, 8 (including 1 injection), 5, and 8 (including 7).
Injection)
.
In this context, the industry believes that the market structure of systemic antibacterial drugs will undergo more changes in the future, and relevant companies need to use innovation to respond in advance
.